Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III

@article{Lethagen1992PharmacokineticsAH,
  title={Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III},
  author={Stephan Lethagen and E Berntorp and Inga Marie Nilsson},
  journal={Annals of Hematology},
  year={1992},
  volume={65},
  pages={253-259}
}
Four different plasma-derived concentrates composed of coagulation factor VIII (FVIII) and von Willebrand factor (vWF) of varying quality (Hemate-P, Behring; Profilate, Alpha; and FVIII-VHP-vWF, C.R.T.S Lille), or almost purified vWF (Facteur Willebrand, C.R.T.S Lille) and one recombinant FVIII concentrate (Recombinate, Baxter) were given, in doses of 30–60 IU VIII:C/kg or 70–110 IU RCof/kg, to five patients with von Willebrand's disease type III, in order to evaluate the role of the vWF in… CONTINUE READING
Highly Cited
This paper has 25 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Interaction between VWF and FVIII in treating VWD.

European journal of haematology • 2015
View 1 Excerpt

Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study.

Haemophilia : the official journal of the World Federation of Hemophilia • 2015

Pharmacokinetics of VWF/FVIII concentrates is a very intricate matter.

Haemophilia : the official journal of the World Federation of Hemophilia • 2011

Haemate P/Humate-P: a systematic review.

Thrombosis research • 2009
View 1 Excerpt

Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.

Haemophilia : the official journal of the World Federation of Hemophilia • 2008

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Clinical and biological evaluation in yon Willebrand ' s disease of avon Willebrand factor concentrate with low F VIII activity

J Goudemand, C Mazurier, A Marcy
1992

Current status of DDAVP formulations and their use

IM Nilsson, S Lethagen
1991

Guidelines for the treatment of yon Willebrand ' s disease with plasma derivatives

F Rodhegiero, JC Gill
1991

In vitro evaluation of a veryhigh - purity , solvent / detergenttreated , von Willebrand factor concentrate

C Mazurier, S Jorieux, C deRomeuf, B Samor, M Goudemand
Vox Sang • 1991

Von Willebrand ' s diseasea therapeutic challenge

LM Aledort
Biomedical Progress • 1991

Clinical and laboratory evaluation of the treatment of von Willebrand ' s disease patients with heat - treated factor VIII concentrate ( BPL 8 Y )

J PasiK, Williams, MS Enayat, Hili FGH
Br J Haematol • 1990